miRagen to Advance Anti-miR-155 Therapy with ALSA Grant

miRagen Therapeutics, a clinical-stage biotechnology company specializing in microRNA-based therapies for rare diseases, has received a grant from the ALS Association to support development of MRG-107 for ALS.   MRG-107 is a synthetic microRNA antagonist that targets miR-155, a pro-inflammatory microRNA whose expression is elevated in the spinal cord of both familial and sporadic ALS patients (Nov 2013 news, Feb 2015 news).  Ablation of miR-155 is SOD1 models of ALS restored microglial function and prolonged survival (Butovksy et al., 2015). The grant will support IND-enabling studies of MRG-107 in collaboration with Howard Weiner’s team from the Brigham and Womens’ Hospital in Boston, MA.

Click here to read the press release.

disease-als topic-preclinical topic-randd
Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail